Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Fineline Cube May 8, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Deals

SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare

Fineline Cube Jul 18, 2024

Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new...

Company Deals

Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio

Fineline Cube Jul 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive...

Company Deals

China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions

Fineline Cube Jul 18, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...

Company Drug

Everest Medicines’ Nefecon Receives NMPA Review, Signaling Potential Treatment Milestone for IgAN Patients

Fineline Cube Jul 18, 2024

Everest Medicines (HKG: 1952), a biopharmaceutical company dedicated to addressing critical medical needs in Asian...

Company

Sanofi to Bolster Hyderabad Facility with $437M Investment, Eyeing Tech Upgrades

Fineline Cube Jul 18, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a leading French multinational pharmaceutical company, has announced plans to...

Company Deals

CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance

Fineline Cube Jul 18, 2024

In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and...

Company Drug

Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China

Fineline Cube Jul 18, 2024

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...

Company Deals

Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai

Fineline Cube Jul 17, 2024

China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish...

Company Deals

Eisai Co., Ltd Secures Asia-Pacific Rights for Fungal Drug with Sato Pharma Deal

Fineline Cube Jul 17, 2024

Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic...

Company Deals

Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie

Fineline Cube Jul 17, 2024

US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm...

Company Drug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo (efgartigimod alfa SC) in gMG

Fineline Cube Jul 17, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE (NASDAQ: ARGX)...

Company Drug

Mabwell Bioscience Lands Orphan Drug Status for B7-H3 Targeting ADC in Small Cell Lung Cancer

Fineline Cube Jul 17, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has been granted Orphan Drug Designation (ODD) by...

Company Drug

Shanghai Pharmaceuticals Secures NMPA Nod for Roche’s Valcyte Generic

Fineline Cube Jul 17, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that it has received marketing approval...

Company Deals

Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs

Fineline Cube Jul 17, 2024

Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research...

Company Drug

Jiangsu Simcere Pharmaceutical’s Quviviq Approval Application Accepted for Review by China’s NMPA

Fineline Cube Jul 17, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), in partnership with Swiss pharmaceutical firm Idorsia Pharmaceuticals...

Company

Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues

Fineline Cube Jul 17, 2024

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a...

Company Drug

Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China

Fineline Cube Jul 17, 2024

Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...

Company Drug

Sino Biopharmaceutical’s Anlotinib Achieves Milestones in Phase III Trial for Soft-Tissue Sarcoma

Fineline Cube Jul 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive...

Company Deals

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

Fineline Cube Jul 17, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company

I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments

Fineline Cube Jul 16, 2024

I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure....

Posts pagination

1 … 324 325 326 … 661

Recent updates

  • Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
  • China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
  • China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access
  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Policy / Regulatory

China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.